The results propose that adults with kind 2 diabetes taking semaglutide have about twice the hazard of having NAION compared to those who do not take this medicine.
Classification ‘very rare’ Side effects indicate that up to 1 in 10,000 users may be affected.NAION is the second most common origin of blindness associated with optic nerve after glaucoma.
Patients experiencing abrupt visual failure or fast visual deterioration while taking semagglutide are advised to search immediate medical attention and to discontinue treatment if NAION is diagnosed.The Danish company Novo Nordisk owns a patent on semaglutide, a GLP-1 receptor agonist utilized to treat kind 2 diabetes and obesity.
It works by expanding insulin secretion and promoting satiety, helping to control blood sugar and weight.A fresh survey besides showed that Ozempic and akin medicines may increase the hazard of kidney cancer.
However, these medicines are reported to reduce the hazard of more than a twelve another cancers, suggesting that their overall benefits may inactive outweigh the risks.
In addition, the EMA has previously investigated reports of suicidal thoughts related to the usage of semaglutide, although no definitive causal relation has been established.The recommendations of the EMA will now be reviewed by the Committee for Medicinal Products for Human usage (CHMP) before a final decision is taken by the European Commission.
Novo Nordisk, who was deposed as Europe's most valuable company at the beginning of this year, stated that he was active in patient safety and collaborates with EMA to update product labels accordingly.
Translated by Google Translator
source\;https://www.rt.com/news/618759-blindness-side-effect-ozempic/
![Królewiec – dawny Kaliningrad. Jak kształtowała się historia miasta? [ZDJĘCIA]](https://static.olsztyn.com.pl/static/articles_photos/40/40796/7ee45ba64e36b52d5d601ebe26002d16.jpg)
